I-Breath Plus

I-Breath Plus Mechanism of Action

ipratropium bromide + salbutamol

Manufacturer:

ACME

Distributor:

Bell-Kenz Pharma

Marketer:

Euro Generics
Full Prescribing Info
Action
Pharmacology: Salbutamol + Ipratropium bromide (i-BREATH PLUS) Metered Dose Inhaler (MDI) is a combination of Salbutamol (as sulfate) and Ipratropium Bromide. It is a hydrofluoroalkane (HFA) based environment friendly inhaler because it does not contain chlorofluorocarbon (CFC) as propellant which is one of the main reasons of ozone layer depletion.
Salbutamol is a short acting beta-adrenergic bronchodilator and Ipratropium bromide is an anticholinergic bronchodilator. When used in combination, Ipratropium bromide prevents the increase in intracellular concentration of cyclic guanosine monophosphate, which are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. i-BREATH PLUS Inhalation Aerosol is expected to maximize the response of the treatment in patients with chronic obstructive pulmonary disease (COPD) by reducing bronchospasm through two distinctly different mechanisms, anticholinergic (parasympatholytic) and sympathomimetic. Simultaneous administration of an anticholinergic (Ipratropium bromide) and a beta2-sympathomimetic (Salbutamol) is designed to benefit the patient by producing a greater bronchodilatory effect than when either drug is utilized alone at its recommended dosage.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in